Jung‐Yoon Choe - Concepedia

Author

Jung‐Yoon Choe

Also Known As

Chung-Il Joung, Hoon-Suk Cha, J Choe, J Y Choe, J. Y. Choe, J.-Y. Choe, J.Y. Choe, JUNG-YOON CHOE, Jennifer Y. Choe, Jung Choe

348

Publications

7.8K

Citations

H-Index

187

Concepts

All Affiliations

Daegu Catholic University Hanyang University Seoul Hospital Chonnam National University Hospital Chungnam National University Hospital Ewha Womans University

About

Jung‐Yoon Choe is an author at Daegu Catholic University specializing in medicine, immunology, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	76	3.7K
2	Health Sciences	12	13	439
3	Natural Sciences	3	3	110
4	Arts	1	1	29
5	Engineering	1	1	16

Jung‐Yoon Choe

142

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial Roy Fleischmann, Eduardo Mysler, Stephen Hall, The Lancet Rheumatoid DisorderRheumatologyTofacitinib MonotherapyMedicineRheumatic Diseases	2017	479
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis Brad H. Rovin, Neil Solomons, William F. Pendergraft, Kidney International Dose-ranging VoclosporinGlomerulonephritisAutoimmune DiseaseSystemic Lupus Erythematosus TreatmentLupus	2018	290
High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry Celi Sun, Julio E. Molineros, Loren L. Looger, Nature Genetics Genome-wide Association StudyAutoimmune DiseaseMedicineGeneticsGenetic Epidemiology	2016	262
Interleukin 1 Receptor Dependence of Serum Transferred Arthritis Can be Circumvented by Toll-like Receptor 4 Signaling Jung‐Yoon Choe, Brian Crain, Sarah R. Wu, The Journal of Experimental Medicine	2003	188
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski, Annals of the Rheumatic Diseases	2015	165
Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells Yun‐Jeong Jeong, Yong-Soo Choi, Jae-Moon Shin, Food and Chemical Toxicology Breast OncologySignaling PathwayMedicineBreast Cancer CellsCancer Growth	2014	139
The prevalence of diffuse idiopathic skeletal hyperostosis in Korea. Seong-Kyu Kim, Byung-Ryul Choi, Chae-Gi Kim, PubMed	2004	134
Prevalence and incidence of gout in Korea: data from the national health claims database 2007–2015 Sang Gyu Kwak, Hwajeong Lee, Seong‐Kyu Kim, Rheumatology International Gouty ArthritisEpidemiologyGoutNational Health Claims	2017	128
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović, Annals of the Rheumatic Diseases	2017	121
The Prevalence of Metabolic Syndrome in Patients with Gout: A Multicenter Study Young Hee Rho, Seong Jae Choi, Young Ho Lee, Journal of Korean Medical Science NutritionMetabolic DisorderGastroenterologyGout PatientsHyperlipidemia	2005	117

Page 1